EC Number |
Recommended Name |
Source Tissue |
Reference |
---|
1.1.1.64 | testosterone 17beta-dehydrogenase (NADP+) |
prostate cancer cell line |
- |
700187 |
1.11.1.9 | glutathione peroxidase |
prostate cancer cell line |
LNCAP and PC-3 |
658933 |
1.8.1.9 | thioredoxin-disulfide reductase |
prostate cancer cell line |
- |
701340 |
2.1.1.1 | nicotinamide N-methyltransferase |
prostate cancer cell line |
- |
757878 |
2.3.1.48 | histone acetyltransferase |
prostate cancer cell line |
DU145 |
685667 |
2.5.1.21 | squalene synthase |
prostate cancer cell line |
- |
674822 |
2.7.1.137 | phosphatidylinositol 3-kinase |
prostate cancer cell line |
- |
707969 |
2.7.1.137 | phosphatidylinositol 3-kinase |
prostate cancer cell line |
PC3M |
688930 |
2.7.1.153 | phosphatidylinositol-4,5-bisphosphate 3-kinase |
prostate cancer cell line |
- |
710406 |
2.7.1.154 | phosphatidylinositol-4-phosphate 3-kinase |
prostate cancer cell line |
- |
739678 |
2.7.10.2 | non-specific protein-tyrosine kinase |
prostate cancer cell line |
- |
738408 |
2.7.11.11 | cAMP-dependent protein kinase |
prostate cancer cell line |
- |
708764 |
2.7.11.18 | myosin-light-chain kinase |
prostate cancer cell line |
- |
709713 |
2.7.12.2 | mitogen-activated protein kinase kinase |
prostate cancer cell line |
- |
682214 |
2.7.7.84 | 2'-5' oligoadenylate synthase |
prostate cancer cell line |
- |
737800 |
3.1.4.39 | alkylglycerophosphoethanolamine phosphodiesterase |
prostate cancer cell line |
- |
6, 663457, 696397 |
3.4.11.2 | membrane alanyl aminopeptidase |
prostate cancer cell line |
APN mRNA expression in hormone-refractory prostate cancer tissue is significantly lower than that in normal prostate tissue |
701038 |
3.4.17.1 | carboxypeptidase A |
prostate cancer cell line |
PC-3m human prostate cancer cell line |
684017 |
3.4.17.21 | Glutamate carboxypeptidase II |
prostate cancer cell line |
prostate cancer cell line |
668866 |
3.4.21.106 | hepsin |
prostate cancer cell line |
used as positive control |
674067 |
3.4.21.117 | stratum corneum chymotryptic enzyme |
prostate cancer cell line |
- |
752620 |
3.4.21.117 | stratum corneum chymotryptic enzyme |
prostate cancer cell line |
ALP is significantly decreased in prostate cancers compared with that in benign prostate epithelial cells. Immunohistochemical expression of kallikrein 7 is observed in prostate epithelial cells, whereas little or no staining is observed in prostate cancer. Western blot analysis reveals that hK7 and antileukoprotease are decreased in malignant prostate epithelium |
695928 |
3.4.21.122 | transmembrane protease serine 2 |
prostate cancer cell line |
- |
753731, 753735 |
3.4.21.B12 | prostase |
prostate cancer cell line |
co-expression of agonist and PAR-2 in primary prostate cancer (benign glands of benign prostatic hyperplasia, prostatic intraepithelial neoplasia and cancer) and prostate cancer bone metastasis |
687699 |
3.4.21.B39 | stratum corneum tryptic enzyme |
prostate cancer cell line |
- |
707624 |
3.4.21.B39 | stratum corneum tryptic enzyme |
prostate cancer cell line |
high expression |
670977 |
3.4.21.B42 | hippostasin |
prostate cancer cell line |
- |
718165 |
3.4.21.B6 | prostasin |
prostate cancer cell line |
- |
676929 |
3.4.22.49 | separase |
prostate cancer cell line |
increased expression of separase |
697382 |
3.4.24.23 | matrilysin |
prostate cancer cell line |
invasive prostate cancer cells, high enzyme expression level |
734609 |
3.4.24.35 | gelatinase B |
prostate cancer cell line |
- |
697383 |
3.4.24.80 | membrane-type matrix metalloproteinase-1 |
prostate cancer cell line |
- |
667519, 669212 |
3.4.24.81 | ADAM10 endopeptidase |
prostate cancer cell line |
cell line LNCaP, localized to the secretory cells of prostate glands, with additional basal cell expression in benign glands |
668275 |
3.4.24.82 | ADAMTS-4 endopeptidase |
prostate cancer cell line |
- |
670737 |
3.4.24.86 | ADAM 17 endopeptidase |
prostate cancer cell line |
TACE expression measured by immunohistochemical analysis is observed in 16 of 24 and 17 of 24 hormone-sensitive and hormone-insensitive prostate carcinomas. TACE expression is predominantly seen in tumors with high levels of released human epidermal growth factor-4 receptor intracellular domain (4ICD) and membranous human epidermal growth factor-4 receptor |
695437 |
3.5.1.23 | ceramidase |
prostate cancer cell line |
- |
734369 |
3.5.1.98 | histone deacetylase |
prostate cancer cell line |
- |
698330 |
3.6.5.2 | small monomeric GTPase |
prostate cancer cell line |
- |
697093 |
4.1.1.28 | aromatic-L-amino-acid decarboxylase |
prostate cancer cell line |
LNCaP cell |
691846 |
5.1.99.4 | alpha-methylacyl-CoA racemase |
prostate cancer cell line |
- |
727330 |